Cord Blood Derived Stem Cells1:
Cord blood (umbilical cord blood) is blood that remains in the placenta and in the attached umblical cord after childbirth. Cord blood is collected because it contains stem cells, which can be used to treat hematopoietic and many other discorder.
Though uses of cord blood beyond blood and immunological disorders is speculative, some research has been done in other areas. Any such potential beyond blood and immunological uses is limited by the fact that cord cells are hematopoietic stem cells (which can differentiate only into blood cells), and not pluripotent stem cells (such as embryonic stem cells, which can differentiate into any type of tissue). Cord blood has been studied as a treatment for diabetes.However, apart from blood disorders, the use of cord blood for other diseases is not in routine clinical use and remains a major challenge for the stem cell community.
Along with cord blood, Wharton's jelly and the cord lining have been explored as sources for mesenchymal stem cells (MSC), and as of 2015 had been studied in vitro, in animal models, and in early stage clinical trials for cardiovascular diseases, as well as neurological deficits, liver diseases, immune system diseases, diabetes, lung injury, kidney injury, and leukemia.
Cord blood is being used to get stem cells with which to test in people with type 1 diabetes mellitus.
The stem cells from umbilical cord blood are also being used in the treatment of a number of blood diseases including blood cancers.
Cord blood is also being studied as a substitute for normal blood transfusions in the developing world More research is necessary prior to the generalized utilization of cord blood transfusion. (Wikipedia).
The amniotic fluid is the protective liquid contained by the amniotic sac of a gravid Amniote. This fluid serves as a cushion for the growing fetus, but also serves to facilitate the exchange of nutrients, water, and biochemical products between mother and fetus.
Amniotic Fluid Allograft:
Amniotic Fluid Allograft was prepared from birth tissues donated after Cesarean Section delivery from a volunteer donor. The Amniotic Fluid was retrieved and processed within 72 hours from time of C-section. The surgical site was prepped according to AORN standards for incision disinfection. Prior to delivery, Amniotic Fluid was aseptically aspirated into a sterile container using a soft suction catheter.
The donor from whom this allograft was derived has been tested and found negative for the following: HBsAg (Hepatitis B Surface Antigen), HBcAb (hepatitis B core antibody), HCV (hepatitis C antibody), HIV I/II-Ab (Antibody to Human Immunodeficiency Virus Types 1 and 2), Syphilis detection test, HIV NAT (HIV Nucleic Acid Test), and HCV NAT (HCV Nucleic Acid Test). Additional donor screening test may have been performed on the donor. If additional tests for Human Immunodeficiency Virus, Hepatitis B, Hepatitis C or Syphilis were performed, the results were reviewed and found to be NEGATIVE. Additional test for other communicable diseases, such as West Nile Virus, T. Cruzi, Cytomegalovirus and Epstein Barr Virus may have been performed. The results of all additional communicable disease tests have been evaluated by the medical director and have been found acceptable according to regulations, standards and SOPs. Donor screening tests are performed by laboratories HCT/P FDA registered, certified under the Clinical Laboratory Improvement Amendments of 1988 (CLIA).
Wharton Jelly Allogarft1:
Wharton’s jelly is a gelatinous substance in the umbilical cord that provides cushioning and support to the umbilical vein and arteries. The cushioning and protective elements from Wharton’s jelly consist of a network of structural proteins, pericytes, mesenchymal stem cells, cytokines, chemokines and growth factors.
Analysis of Structural Wharton’s Jelly:
Disclaimer: This information is for general knowledge purpose only, LRMT uses products from manufacturing providers registered with FDA, All protocols of isoloation of amniotic fluid allogarft or Wharton Jelly Allogarft may be proprietary, patient will be provided with full prodcuct details and specific use guidelines before selecting any therapies.
1. Predictive Biotech: CorCyteTM
2.(1) Citations on file:PBIO-GRID-CITATIONS,PBIO-DOC-PRODUCT-CC,v2.0, 10/30/2017